Healthcare Enterprise Group rebuilds platform for innovative product R&D (research & development)
This article was originally published in Clinica
When UK AIM-listed Healthcare Enterprise Group's medical technologies business model ran into trouble in late 2005, two board members stepped up to lead a recovery. Nine months and some radical decision-making later, the original business plan has been slotted back in place. HCEG non-executive chairman Mark Tompkins told Ashley Yeo what happened, why and what comes next
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.